Evidence map›Paper›PMID 35550909›Full record

ArticleJournal of magnetic resonance (San Diego, Calif. : 1997)2022

HIV-1 VIF and human APOBEC3G interaction directly observed through molecular specific labeling using a new dual promotor vector.

Wazo Myint, Celia A Schiffer, Hiroshi Matsuo

Open access · greenAbstract read
In one paragraph

Article in Journal of magnetic resonance (San Diego, Calif. : 1997), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Wazo MyintBasic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Celia A SchifferDepartment of Biochemistry and Molecular Biotechnology, University of Massachusetts Chan Medical School, Worcester, MA 01655, USA.
Hiroshi MatsuoBasic Science Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA. Electronic address: hiroshi.matsuo@nih.gov.
Frederick National Laboratory for Cancer Research · USUniversity of Massachusetts Chan Medical School · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI PENDLETON, RICHARD · 2019 to 2025
$3932.6M
Structural studies of biomolecules related to cancer and HIV-AIDSZICBC011849 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MATSUO, HIROSHI · 2018 to 2024
$5.0M
Structurally dissecting APOBEC3's for HIV-1 restriction and beyondR01AI150478 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SCHIFFER, CELIA A. · 2019 to 2024
$3.9M
Structurally dissecting APOBEC3's for HIV-1 restrictionR01GM118474 · NIGMS · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI SCHIFFER, CELIA A. · 2016 to 2018
$1.8M
NCI NIH HHS 75N91019D00024NIAID NIH HHS R01 AI150478NIGMS NIH HHS R01 GM118474
6 · The paper itself

Abstract

Over the last few decades, protein NMR isotope labeling methods using E. coli based expression have revolutionized the information accessible from biomolecular NMR experiments. Selective labeling of a protein of interest in a multi-protein complex can significantly reduce the number of cross-peaks and allow for study of large protein complexes. However, limitations still remain since some proteins are not stable independently and cannot be separately labeled in either NMR active isotope enriched or unenriched media and reconstituted into a multimeric complex. To overcome this limitation, the LEGO NMR method was previously developed using protein expression plasmids containing T7 or araBAD promoters to separately express proteins in the same E. coli after changing between labeled and unlabeled media. Building on this, we developed a method to label the Human Immunodeficiency Virus type 1 viral infectivity factor (HIV-1 Vif), a monomerically unstable protein, in complex with CBFβ, it's host binding partner. We designed a dual promoter plasmid containing both T7 and araBAD promoters to independently control the expression of HIV-1 Vif in NMR active isotope enriched media and CBFβ in unenriched media. Using this method, we assigned the backbone resonance and directly observed the binding of HIV-1 Vif with APOBEC3G, a host restriction factor to HIV-1.

Indexed as

APOBEC-3G DeaminaseHIV-1vif Gene Products, Human Immunodeficiency VirusEscherichia coliHumansPromoter Regions, GeneticAPOBEC-3G DeaminaseAPOBEC3G protein, humanvif Gene Products, Human Immunodeficiency Virusvif protein, Human immunodeficiency virus 1APOBEC3GCBFβDouble promoter plasmidHIV-1 VifMolecular-specific labeling

Identifiers

PMID35550909
PMCPMC9149140
OpenAlexW4224981437

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.